Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

INTRODUCTION: To examine the utility of sequential versus dual add-on approaches in patients who have type 2 diabetes and inadequate glycemic control with metformin therapy alone, we characterized the efficacy and safety of dual therapy with dapagliflozin or saxagliptin added to metformin in the ope...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Ther
Main Authors: Mathieu, Chantal, Catrinoiu, Doina, Ranetti, Aurelian Emil, Johnsson, Eva, Hansen, Lars, Chen, Hungta, Garcia-Sanchez, Ricardo, Iqbal, Nayyar, Celiñski, Aleksander
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2018
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://ncbi.nlm.nih.gov/pubmed/29802530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0445-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados